These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 28008769)

  • 21. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
    Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M
    Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
    Taheri S; Sahraian MA; Yousefi N
    J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
    J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.
    Furneri G; Santoni L; Ricella C; Prosperini L
    BMC Health Serv Res; 2019 Jun; 19(1):436. PubMed ID: 31253138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.